Skip to content
AnalystLens

AbbVie Inc. 8-K Report, Corporate Update (Feb 26, 2024)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed February 26, 2024
Period End
February 22, 2024
Security
ABBV
In the record · 2016–202610-K1110-Q328-K163

ABBV filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 163 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’16Nov ’16
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Nov ’22Nov ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 26, 2024. Cited figures are marked; the original filing is the authoritative source.

AbbVie Inc. (ABBV) announced on February 26, 2024, that it has entered into an underwriting agreement to issue and sell $15.0 billiona in aggregate principal amount of senior notes.

These notes are offered in various denominations and maturities, ranging from 2027 to 2064, with coupon rates varying from 4.800%b to 5.500%. This significant debt issuance is intended to strengthen AbbVie's financial position and fund key strategic initiatives.

The primary uses of the net proceeds from this offering are to prepay a $5.0 billionc term loan, the proceeds of which were used for the ImmunoGen acquisition, and to fund AbbVie's pending acquisition of Cerevel Therapeutics Holdings, Inc. Additionally, funds will be allocated to repay outstanding commercial paper borrowings and for general corporate purposes. This move indicates a proactive approach by AbbVie to manage its debt structure and finance its growth strategies.

02—Key points

Key Highlights

  1. AbbVie is issuing $15.0 billion in senior notes with maturities between 2027 and 2064.
  2. The senior notes carry interest rates ranging from 4.800% to 5.500%.
  3. Proceeds will be used to repay a $5.0 billion term loan related to the ImmunoGen acquisition.
  4. A significant portion of the funds will be used to finance the pending acquisition of Cerevel Therapeutics Holdings, Inc.
  5. The offering also aims to repay outstanding commercial paper borrowings.
  6. The notes are unsecured, unsubordinated obligations of AbbVie.
  7. The offering is being conducted through a registered public offering with multiple underwriters.

03—Questions

Frequently Asked Questions

  1. What is the total amount of senior notes AbbVie is issuing?

    AbbVie is issuing a total of $15.0 billion in aggregate principal amount of senior notes.

  2. How will the proceeds from this debt issuance be used?

    The proceeds will be used primarily to prepay a $5.0 billion term loan (used for the ImmunoGen acquisition), to fund the pending acquisition of Cerevel Therapeutics Holdings, Inc., to repay outstanding commercial paper, and for general corporate purposes.

  3. What are the maturity dates and interest rates for these new notes?

    The senior notes have various maturity dates between 2027 and 2064, with annual interest rates ranging from 4.800% to 5.500%.

  4. Are these notes secured or unsecured?

    The notes are unsecured and unsubordinated obligations of AbbVie, ranking equally with other existing and future unsecured, unsubordinated indebtedness.

04—Continue

← View all 8-K filings